Founded in 2015, Omnix Medical focuses on developing advanced anti-infective treatments for life-threatening bacterial infections. The newly secured funding will enable the company to complete Phase II proof-of-concept studies for its lead compound, OMN6, which targets infections caused by Gram-negative bacteria, including Acinetobacter baumannii strains resistant to last-line antibiotics such as carbapenems and colistin.
The investment will also support Omnix Medical’s regulatory activities, manufacturing scale-up, and the continued advancement of its pipeline of engineered antimicrobial peptides, positioning the company at the forefront of combating antibiotic resistance.
“The rise of antibiotic-resistant infections is not just a medical crisis, it is a societal one. At Harel, we are dedicated to supporting innovation and biotech, and we believe that companies like Omnix are essential to ensuring the development of effective treatments that protect lives and promote long-term wellbeing,” said Tomer Goldberg, Vice President and Managing Director of Harel Technology Investments at Harel Insurance & Finance.
Dr. Moshik Cohen-Kutner, CEO of Omnix Medical, expressed his confidence in the company’s strengthened position, stating: “With the co-leadership of Harel Insurance & Finance and the EIC Fund, and the strong continued support of our existing shareholders, we now have the resources to complete Phase II proof-of-concept studies of OMN6, strengthen our regulatory and manufacturing capabilities, and advance our entire pipeline. We are proud to have both the backing of new investors and the renewed trust of our long-standing shareholders. Together, they reflect the confidence in Omnix’s mission to deliver truly novel anti-infective solutions.”
Dr. Niv Bachnoff, Chief Scientific Officer at Omnix Medical, highlighted OMN6’s unique mechanism of action, explaining: “OMN6’s selectivity for bacterial membranes, its rapid pore-forming activity, and its engineered stability represent a fundamentally different approach to combating resistant pathogens. These qualities not only enable rapid and effective treatment but also significantly reduce the likelihood of resistance development. With this funding, we are positioned to demonstrate OMN6’s potential to transform the treatment of multidrug-resistant infections.”
The Series C investment marks a significant milestone for Omnix Medical, enabling the company to accelerate clinical development and bring forward innovative solutions to address the global crisis of antibiotic resistance.
